Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia
| Autor: | Eleni Bairaktari, Haralampos J. Milionis, K. Seferiadis, Moses Elisaf, Vasilios G. Athyros, Sofia Tsouli, Anna I. Kakafika |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
medicine.medical_specialty
Creatinine Fenofibrate Triglyceride business.industry Atorvastatin nutritional and metabolic diseases medicine.disease chemistry.chemical_compound Endocrinology chemistry Simvastatin Internal medicine Hyperlipidemia medicine Uric acid lipids (amino acids peptides and proteins) cardiovascular diseases Hyperuricemia Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | American Heart Journal. 148:635-640 |
| ISSN: | 0002-8703 |
| DOI: | 10.1016/j.ahj.2004.04.005 |
| Popis: | Background Epidemiologic studies have shown that serum uric acid is a risk factor of coronary artery disease. In addition to fenofibrate, there is some evidence that atorvastatin may have a hypouricemic action, but the underlying mechanisms remain speculative. Methods This randomized trial was conducted to investigate the effects of atorvastatin and simvastatin on uric acid homeostasis in patients treated for primary hyperlipidemia. A total of 180 patients were enrolled; patients were randomly assigned to 40 mg/d of either atorvastatin or simvastatin. Serum lipid and metabolic parameters were measured at baseline and at 6 and 12 weeks of treatment; random urine samples were simultaneously obtained for creatinine, sodium, and uric acid determinations. Results Baseline serum uric acid levels correlated positively with the body mass index, serum insulin, creatinine, and triglyceride levels and inversely with serum HDL cholesterol levels. Both statins caused a favorable effect on lipids and a significant decrease in fibrinogen and high-sensitivity CRP levels. However, only atorvastatin reduced serum uric acid levels (from 5.6 ± 1.7 to 4.9 ± 1.5 mg/dL, P P P = .008). Conclusions Atorvastatin (but not simvastatin) significantly lowered serum uric acid levels. This result may be in favor of a preferable choice of atorvastatin for the treatment of hyperlipidemic patients presenting with hyperuricemia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect